A phase III comparison of methyl-CCNU + vincristine with or without BCG + allogeneic tumor cells in metastatic melanoma
| Autor: | M.J. Mastrangelo, David Berd, R.E. Bellet |
|---|---|
| Rok vydání: | 1979 |
| Předmět: |
Cancer Research
Vincristine medicine.medical_specialty Chemotherapy business.industry Melanoma medicine.medical_treatment Immunology Tumor cells Methyl CCNU medicine.disease Gastroenterology Surgery Oncology Chemoimmunotherapy Tumor progression Internal medicine Toxicity medicine Immunology and Allergy business medicine.drug |
| Zdroj: | Cancer Immunology Immunotherapy. 6 |
| ISSN: | 1432-0851 0340-7004 |
| DOI: | 10.1007/bf00200210 |
| Popis: | Sixty-two patients with metastatic malignant melanoma were randomized to treatment with either (a) methyl-CCNU (200 mg/m2, PO every 8 weeks) plus vincristine (2 mg IV every 4 weeks), or (b) the same chemotherapy plus intradermal (ID) injections of irradiated (15,000 rads) allogeneic (fresh-frozen) melanoma cells (1–2×108) admixed with BCG (Glaxo, 2–4.5×106 organisms) every 2 weeks. Treatment cycles were repeated every 8 weeks until tumor progression. Seven (2 CR, 5 PR) objective remissions were noted among 31 patients (22.5%) treated with chemotherapy alone, whereas six (3 CR, 3 PR) objective remissions were noted among 31 patients (19%) treated with chemoimmunotherapy (P>0.05). The medians for remission duration (6 months) and survival (6.5 months) in the chemotherapy group did not differ significantly from the medians for remission duration (8 months) and survival (8 months) in the chemoimmunotherapy group. The patients manifested no unexpected toxicity. Hematologic toxicity was experienced by patients on both regimens; however, those receiving chemoimmunotherapy rebounded more quickly. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink